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Summary The elevation of plasma L-arginine levels stimulates nitric oxide (NO)
synthesis, but the underlying mechanisms are not yet understood. We examined the
role of physiological changes in pulmonary arteries on endogenous NO production.
Male Wistar rats were divided into following groups: (1) control rats receiving normal
water orally, (2) ARG rats receiving L-arginine water orally, (3) MCT rats injected with
monocrotaline (MCT) on day 0 and receiving normal water orally, and (4) MCTþARG
rats injected with MCT on day 0 and receiving L-arginine water orally. The rats were
studied after 23 days of dietary intervention. In MCTþARG rats, supplemental L-
arginine exhibited a significant pulmonary vasodilatory effect, as shown by a
decreased pulmonary arterial pressure (PAP) (Po0.001), decreased right ventricular
hypertrophy (Po0.01), and improved endothelium-dependent relaxation (Po0.01).
Also L-arginine inhibited the elevation of plasma endothelin-1 (Po0.01). Oral L-
arginine administration increased plasma L-arginine levels about twofold, but in only
MCTþARG rats (i.e., not in ARG rats) did the urinary nitrate excretion significantly
increase (Po0.05), which is an indicator of endogenous NO formation. Oral
administration of L-arginine is effective against pulmonary vascular remodeling.
The data also suggest that the initial elevation of PAP is important for the induction of
endogenous NO synthesis.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
The severity of pulmonary hypertension is one of the
most important determinants of the prognosis of
congenital and acquired heart diseases. Reduced
production of nitric oxide (NO; a potent endogenous
vasodilator) in endothelial cells of the pulmonary
arteries contributes to the progression of pulmonary
hypertension.1 Therefore, the promotion of endo-
genous NO production in endothelial cells of the
pulmonary arteries can be an alternative therapy for
controlling pulmonary hypertension.2,3 NO is synthe-
sized in vascular endothelial cells by the action of
endothelial NO synthase (eNOS) on L-arginine, which
is converted to L-citrulline and NO,4 and its produc-
tion can be further stimulated by a variety of
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receptor agonists as well as by the shear stress
produced by vascular flow.5–7
It has been reported that oral L-arginine admin-
istration to cholesterol-fed rabbits with athero-
sclerosis improves endothelium-dependent
relaxation, inhibits platelet aggregation, and re-
duces atheroma and intimal hyperplasia.8 Oral
supplementation of L-arginine is simple to imple-
ment clinically, but there are few studies on the
effects of oral administration of L-arginine in
pulmonary hypertensive animal models. The eleva-
tion of plasma L-arginine levels stimulates NO
synthesis, but the relationship between changes
in plasma L-arginine levels and the rate of
endogenous NO formationFand the underlying
mechanismsFare not fully understood. We hy-
pothesized that hemodynamic changes such as
elevation of arterial pressure and/or sheer stress
in pulmonary arteries might strongly affect endo-
genous lung NO production.
Here we describe the effects of oral administra-
tion of L-arginine on monocrotaline (MCT)-induced
pulmonary hypertension in rats. We also examined
the effects of physiological changes in pulmonary
arteries on endogenous NO production.
Methods
Animals
The experimental procedures are shown in Fig. 1.
Four-week-old male Wistar rats weighing 94–108 g
(SLC, Shizuoka, Japan) were divided into four
groups as follows: (i) rats injected with 0.9% saline
vehicle and receiving normal water throughout the
course of the study (control rats, n¼ 10), (ii) rats
injected with vehicle and receiving 2.25% L-arginine
in their drinking water (ARG rats, n¼ 6), (iii) rats
injected with MCT (40mg/kg) and receiving normal
water (MCT rats, n¼ 21), and (iv) rats injected with
MCT (40mg/kg) and receiving 2.25% L-arginine
water (MCTþARG rats, n¼ 22). This oral dosage
of L-arginine water has been shown to restore NO
production in hypercholesterolemic animals.9 MCT
(Aldrich, WI, USA) was dissolved in 1.5ml of 1 N
HCl, adjusted to pH 7.4 with 1N NaOH, and diluted
with distilled water to a concentration of 20mg/
ml. The rats were given a single subcutaneous
injection of either MCT or vehicle on day 0, and
then studied after 23 days of dietary intervention.
They were given food and water ad libitum and
housed in 12 h/12 h light/dark conditions at
2370.51C and a relative humidity of 5575%. All
experiments were performed according to proto-
cols approved by the animal use and care commit-
tee of Nagoya City University Graduate School of
Medical Sciences.
Collection and measurement of urine
excretion of nitrate
On day 22 after the injection of MCT, the rats were
placed in metabolic cages for 24 hours to collect
urine samples. Each sample was frozen at 201C
until the urine concentration of nitrate, a metabo-
lite of L-arginine in NO production, was measured
by high-performance liquid chromatography (HPLC;
SRL, Tokyo, Japan).
Measurement of systemic arterial pressure
and pulmonary arterial pressure
After completing the collection of urine samples (on
day 23), the rats were anesthetized with an
intraperitoneal injection of pentobarbital sodium
(33mg/kg). An arterial catheter of silastic tube
(0.31mm ID and 0.64mm OD) flushed with hepar-
inized saline was inserted via the left carotid artery
into the descending aorta, and another catheter was
inserted via the right jugular vein into the pulmon-
ary artery by a closed-chest technique under
spontaneous breathing.10 Both systemic arterial
pressure and pulmonary arterial pressure (PAP) were
measured using a pressure transducer and amplifier
system (IB-160, Fukuda Denshi, Tokyo, Japan).
Blood sampling and measurement of plasma
L-arginine and endothelin-1 levels
Blood samples were drawn from the left carotid
artery and collected into plastic tubes containing
heparin for the measurement of L-arginine, and
containing EDTA (ethylenediaminetetraacetic acid)
and aprotinin for the measurement of endothelin-1
(ET-1). The samples were then centrifuged at 2000g
for 10min at 41C to isolate the plasma. The plasma
was frozen at –201C until its concentrations of L-
arginine and ET-1 were measured.
The plasma concentration of L-arginine was
measured by HPLC. The plasma concentration of
ET-1 was measured using a commercially available
ET-1,21-specific radioimmunoassay system (SRL).
Examination of ventricular weight
The heart and lungs were removed and weighed, and
then the right ventricular free wall was separated
from the left ventricle and septum. The organ-to-
body-weight ratios were calculated for the respec-
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tive organs. Specifically, we used the ratio of the
weight of the right ventricle to the weight of the left
ventricle plus septum [RV/(LVþ S)] as an index of
right ventricular hypertrophy.
Measurement of endothelium-dependent
relaxation of the pulmonary artery
Pulmonary arteries were separated carefully from
both the heart and lungs and placed in modified
Krebs–Henseleit solution at room temperature in
preparation for measuring the endothelium-depen-
dent relaxation. The composition of the solution
was as follows (in mM): Naþ , 134; Kþ , 5.9; Mg2þ ,
1.2; Ca2þ , 2.5; HCO3 , 15.5; H2PO

4 , 1.2; Cl
, 137;
and glucose, 15.5. A segment of the intrapulmonary
artery was dissected and cut. A 2-mm-long ring
segment of the intrapulmonary artery was cleaned
of fat and connective tissue and suspended verti-
cally between two stainless steel wires in a
recording chamber containing the buffer solution.
One of the wires was anchored and the other was
connected to a mechanoelectric transducer (TB-
612 T, Nihon Kohden, Tokyo, Japan) connected to a
carrier amplifier (SEN-6102M, Nihon Kohden, To-
kyo, Japan) to measure isometric forces.
Cumulative concentration–response relaxation
curves to acetylcholine were obtained in each ring.
After a steady state of precontraction with nora-
drenaline (106 M) was reached, the dose–response
characteristic to acetylcholine (108–105 M) was
obtained to assess the endothelial vasodilatory
response. (The relaxation responses presented here
are expressed as a percentage of the precontractile
tension induced with noradrenaline.) The rings
were allowed to re-equilibrate in drug-free buffer
for 40min until the tension between experimental
cycles returned to the original baseline. The
responses were recorded using a chart recorder
(VP-6524A, Panasonic, Tokyo, Japan).
Statistical analysis
All the data are expressed as means 7SE. For
hemodynamic assessment, measurement of right
ventricular weight, and analysis of plasma L-
arginine levels, ET-1 levels, and urinary nitrate
excretion, data were analyzed statistically using
one-way ANOVA and followed by Scheffe’s F test
when significant differences were found. Changes
in body weight and endothelium-dependent relaxa-
tion responses were analyzed with repeated-mea-
sures ANOVA followed by Scheffe’s F test, and
comparisons among the groups at each measuring
points were made by one-way ANOVA followed by
Scheffe’s F test. Differences with a P value less
than 0.05 were considered significant.
Results
Body weight
The changes in body weight are summarized in
Table 1. All rats gained weight steadily, but
compared with control and ARG rats, body-weight
gains in MCT and MCTþARG rats were inhibited
from day 7 to day 23 (Po0.001). Treatment with L-
arginine did not affect body-weight gain.
Progressive changes in hemodynamics, right
ventricular hypertrophy, and plasma ET-1
levels
Mean PAPs are shown in Fig. 2A. MCT rats exhibited
significant pulmonary hypertension, as indicated by
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Figure 1 Experimental procedures.
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the PAP (41.671.4mmHg) being higher than that in
control rats (21.470.6mmHg, Po0.001). Treat-
ment with L-arginine in MCTþARG rats reduced the
elevation of PAP (30.471.4mmHg, Po0.001 vs.
MCT rats). However, L-arginine treatment did not
affect PAP in ARG rats (20.770.6mmHg). Treat-
ment with L-arginine did not produce any significant
differences in the PAPs of normal rats.
The systemic arterial pressure was the same in all
groups: 113.274.1mmHg in control rats,
115.574.2mmHg in ARG rats, 115.674.5mmHg
in MCT rats, and 112.273.5mmHg in MCTþARG
rats (Fig. 2B). Treatment with L-arginine did not
influence systemic arterial pressure.
MCT rats developed right ventricular hypertro-
phy, and RV/(LVþ S) was higher in MCT rats
(0.4470.03) than in control rats (0.2570.01,
Po0.001; Fig. 2C). Treatment with L-arginine
attenuated right ventricular hypertrophy, as shown
by the decrease in RV/(LVþ S) in MCTþARG rats
(0.3470.02, Po0.01 vs. MCT rats). There were no
significant differences in RV/(LVþ S) between con-
trol rats and ARG rats (0.2470.01).
The plasma ET-1 concentration in MCT rats
(9.271.0 pg/ml) was higher than in control rats
(4.370.6 pg/ml, Po0.001; Fig. 2D). Treatment
with L-arginine in MCTþARG rats markedly inhib-
ited this elevation of plasma ET-1 levels
(5.370.3 pg/ml, Po0.01 vs. MCT rats). There were
no statistically significant differences in plasma ET-
1 levels among control, ARG (4.571.0 pg/ml), and
MCTþARG rats.
Plasma L-arginine levels and urinary
excretion of nitrate
Plasma L-arginine concentrations increased signifi-
cantly in both ARG and MCTþARG rats
(420730 nmol/ml and 322753 nmol/ml, respec-
tively) compared to that in control rats
(158710 nmol/ml, Po0.001 and Po0.01, respec-
tively; Fig. 3A). In MCT rats, the plasma concentra-
tion of L-arginine was slightly reduced
(115716 nmol/ml), but the difference was not
significant.
Urine excretion of nitrate increased after 23 days
of oral administration of L-arginine in MCTþARG
rats (29.971.7 nmol/g BW/day) compared to that
in control rats (19.672.3 nmol/g BW/day, Po0.05;
Fig. 3B). However, the level of urine nitrate in ARG
rats was not elevated (19.373.9 nmol/g BW/day).
The urine nitrate level in MCT rats was slightly
reduced (17.472.0 nmol/g BW/day), but the dif-
ference was not significant.
Effect of long-term oral administration of L-
arginine on endothelium-dependent
relaxation
Figure 4 shows that the endothelium-dependent
relaxation response to acetylcholine (108–105 M)
in MCT rats was lower than that in control rats
(Po0.001). The relaxation response in MCTþARG
rats was also less than that in control rats
(Po0.001), but it was greater than that in MCT
rats (Po0.01). The MCT injection damaged en-
dothelium-dependent vasodilation, but this nega-
tive effect was inhibited by oral administration of L-
arginine.
Discussion
NO is very rapidly oxidized to nitrite and nitrate
in vivo, and the greater part of the metabolites is
excreted into the urine in the form of nitrate, so
that urinary nitrate excretion has been suggested
to be a reliable indicator of NO formation.11,12 In
the present study, oral administration of L-arginine
had a significant pulmonary vasodilatory effect and
prevented vascular endothelium dysfunction. More-
over, the pulmonary vasodilatory effect and the
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Table 1 Body-weight changes after MCT or saline injection.
Body weight (g)
Day 0 Day 7 Day 14 Day 21 Day 23
Control (n¼ 8) 10171 14671 19972 24773 25673
ARG (n¼ 6) 10171 13874 20774 25074 26475
MCT (n¼ 21) 9871 12672nnn 17272nnn 21373nnn 21473nnn
MCTþARG (n¼ 20) 9971 12972nnn 17672nnn 21874nnn 22074nnn
Effects of MCT injection and oral L-arginine administration on body-weight gain in rats. Final body weights were lower in MCT
and MCTþARG rats than in control and ARG rats. Treatment with L-arginine did not affect body-weight gains.
nnnPo0.001 vs. control rats at the same time points.
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elevation in urinary nitrate excretion occurred
selectively in rats treated with MCT and receiving
L-arginine orally. NO is derived from many sources
besides endothelial cells in pulmonary arteries such
as in systemic arteries or kidneys.6,13 Although
there is the possibility that increased urine nitrate
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Figure 2 Effects of oral L-arginine administration for 23 days on mean PAP, mean systemic arterial pressure, RV/
(LVþ S), and plasma ET-1 levels in rats injected with either MCT or vehicle. L-Arginine significantly reduced mean PAP
and attenuated right ventricular hypertrophy in MCTþARG rats, but not in ARG rats. Treatment with L-arginine
markedly inhibited the elevation of plasma ET-1 levels. *Po0.05 vs. control rats, ***Po0.001 vs. control rats, wPo0.01
vs. MCT rats, zPo0.001 vs. MCT rats.
Figure 3 Oral L-arginine administration increased plasma L-arginine levels, but urine nitrate levels increased only in
MCTþARG rats. *Po0.05 vs. control rats, **Po0.01 vs. control rats, ***Po0.001 vs. control rats.
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reflects NO synthesis in other tissues except lungs,
the specific pulmonary vasodilatory effect and
prevention of vascular endothelium dysfunction in
MCT rats with L-arginine suggest that lung NO
production is the most important and contributes
to the amelioration of pulmonary hypertension.
In our studies, urine excretion of nitrate did not
increase in normal rats receiving L-arginine, but
only increased in rats treated with MCT and
receiving L-arginine orally. Also in hemodynamic
studies, supplementation with L-arginine did not
affect PAP and systemic arterial pressure in normal
rats. We speculate that administration of L-arginine
had no effect on urine excretion and hemodynamics
in normal rats because they were not subjected to
an initial elevation of PAP and other hemodynamic
forces sufficient to induce endogenous NO produc-
tion. This finding is consistent with the idea that
the concentration of endogenous L-arginine in
endothelial cells in normal pulmonary vascular
beds (as in other fresh vascular tissues) is sufficient
to prevent rate limiting of the first step in the
conversion of L-arginine to NO.14 A single subcuta-
neous injection of MCT produces vascular endothe-
lial damage, medial-wall thickening, and a
progressive decrease in lumen diameter in pulmon-
ary arteries.15,16 These effects will increase the
fluid sheer stress in the pulmonary arteries when
blood flow does not change. Previous in vitro
experiments showed that the release of NO, as
assessed by measuring increases in soluble guany-
late cyclase activity in the presence of acetylcho-
line, was stimulated by high shear stress.5 Other
experimental data indicate that pulmonary eNOS
expression in vivo is upregulated by shear stress and
increased pulmonary blood flow.7 Vascular endothe-
lial cells respond to mechanical stress and hemo-
dynamic forces by altered gene expression and by
undergoing significant structural reorganization.17
Taken together with our results, it is conceivable
that a physiological stimulus in vivo, such as a
change in PAP, increases of fluid shear stress or
pulsatile stretching of the vessel wall, is necessary
to induce a vasodilatory effect via the L-arginine–
NO pathway.
It has been reported that eNOS plays major roles
in NO induction in terms of the vasodilatory effect
and the prevention of vascular remodeling in
pulmonary hypertension.18,19 In contrast, the role
of inducible NO synthase (iNOS) is not clearly
understood,20 and there have also been discrepan-
cies between iNOS mRNA expression and iNOS
protein levels in animal models.21,22 iNOS expres-
sion is known to be induced by lipopolysaccharide
and inflammatory cytokines.23 A recent study
reported an association between iNOS expression
and advanced lesion of human pulmonary plexo-
genic arteriopathy caused by flow-associated pul-
monary hypertension.24 In MCT models, the severe
inflammatory changes in lung tissue mean that the
contribution of iNOS to NO production in the lungs
has to be considered. The present study did not
examine the influence of lung iNOS on endogenous
NO synthesis and vascular remodeling, and hence
further functional studies involving various forms
and severities of pulmonary hypertension are
needed to clarify this issue.
Endothelium-dependent relaxation has been
shown to be impaired in patients with chronic
obstructive lung disease,25 and the vasodilatory
response to acetylcholine is diminished in experi-
mental pulmonary hypertensive animal models.26 In
the present study, administration of L-arginine in
drinking water for 23 days improved endothelium-
dependent relaxation of isolated pulmonary artery
rings in MCT-induced pulmonary hypertension. This
finding suggests that in vivo administration of L-
arginine is important to the efficacy of NO produc-
tion and maintenance of endothelium function in
the pulmonary artery.14 Previous experiments on
endothelium-dependent relaxation of pulmonary
arteries showed that in vitro perfusion of L-arginine
restored the endothelium-dependent vasodilatory
response in perfused lung models from MCT-treated
and hypoxic rats.14,27 In contrast, incubating
pulmonary artery rings isolated from either MCT-
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Figure 4 Effects of long-term oral administration of L-
arginine on the endothelium-dependent relaxation re-
sponse to acetylcholine (108–105 M). Precontraction
induced by noradrenaline (106 M) was taken as 100%.
*Po0.05 vs. control rats at the same dose of acetylcho-
line, **Po0.01 vs. control rats at the same dose of
acetylcholine, ***Po0.001 vs. control rats at the same
dose of acetylcholine, xPo0.05 vs. MCT rats at the same
dose of acetylcholine, wPo0.01 vs. MCT rats at the same
dose of acetylcholine.
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treated and hypoxic rats in an L-arginine organ bath
did not affect the endothelium-dependent vasodi-
latory response.28,29 Arterial ring segments are not
subjected to the same forces as pulmonary arteries
in situ.26 These discrepancies in the vasodilatory
effects of L-arginine between perfused lungs and
isolated pulmonary rings may therefore be attribu-
table to a difference in the intraluminal perfusion
pressure of the pulmonary arteries between the
two methods.27
Previous studies demonstrated that tissue and
plasma levels of ET-1, a potent endothelium-
derived contracting factor, are elevated both in
animal models and in patients with pulmonary
hypertension,30,31 with plasma ET-1 correlating
particularly well with the extent of pulmonary
hypertension and reflecting the abnormalities of
pulmonary circulation.32,33 The present study also
demonstrates that oral L-arginine administration
successfully inhibited the elevation of plasma ET-1
levels, indicating that this treatment is beneficial
in view of the maintenance of pulmonary circula-
tion.
In summary, oral administration of L-arginine is
effective against vascular remodeling via an L-
arginine–NO pathway in severe experimental pul-
monary hypertension induced by MCT. In human
studies, administration of L-arginine has a beneficial
effect in patients with pulmonary hypertension.34,35
It is possible that oral supplementation of L-arginine
will be a useful clinical therapy for pulmonary
hypertension, although the safety of its long-term
administration still needs to be examined.
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